Press Releases

 
Press Releases
  Date Title and Summary View
Jan 19, 2009
Fremont, Calif., January 19, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company’s chief scientific officer, will present at the 13th Annual Drug Delivery Partnerships Meeting in Las Ve...
Dec 9, 2008
Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that it has completed  an  End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its ZP-PTH rapid delivery...
Dec 9, 2008
Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that it has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its ZP-PTH rapid delivery patch for the treat...
Oct 27, 2008
Fremont, Calif. – October 27, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced positive results from its phase 2, randomized, multi-center, double-blind, multi-dose study designed to determine safety and efficacy of its ZP-PTH rapid deliv...
Oct 23, 2008
Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief Financial Officer of Zosano will present at the 7th annual BIO Investor Forum. Mr. Vuko will...
Sep 11, 2008
Fremont, Calif. – September 11, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of Zosano PTH Patch, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the tre...
Sep 8, 2008
Fremont, CA – September 8, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that Gail Schulze has joined the company as chair and CEO. The company also announced several recent appointments to the Zosano leadership team, including Don Brown, ...
Nov 28, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc. announced today that it has closed enrollment of its Phase 2 clinical trial evaluating a parathyroid hormone (hPTH 1-34) transdermal microprojection delivery system to treat post menopausal women with osteoporosis who are at a high risk of bone fracture. This enrollment was completed ahead of...
Nov 15, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products using innovative drug delivery, has announced the receipt of the second half of its initial venture funding of $45 million, for a total investment of $90 million. Four venture capital firms, New...
Sep 27, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Sept. 27, 2007--The Macroflux Corporation announced today that it has changed the name of the company to Zosano Pharma, Inc. "Our name change reflects the positive evolutionary steps the company is taking to advance our innovative transdermal microprojection delivery system technology," said M. Cory Zwerl...
Page: FirstPrevious ...
8
NextLast
= add release to Briefcase